Veracyte to Present at Upcoming Investor Conferences

·2 min read

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman, chief executive officer and incoming executive chairman, and Marc Stapley, incoming chief executive officer, are scheduled to participate in two upcoming virtual investor conferences:

  • UBS Global Healthcare Virtual Conference
    Fireside Chat on Tuesday, May 25, 2021, at 10:00 a.m. EDT

  • 7th Annual Truist Securities 2021 Life Sciences Summit
    Fireside Chat on Thursday, May 27, 2021, at 12:30 p.m. EDT

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at Replays of the webcasts will be available for 90 days following the conclusion of each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit and follow the company on Twitter (@veracyte).

View source version on


Investor and Media Contact:

Tracy Morris
Vice President of Corporate Communications
& Investor Relations

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting